Blog

Sep 2, 2015

Update in Amgen v. Sandoz

On August 31, 2015, to support the launch of its Zarxio™ (a biosimilar of Amgen's Neupogen® (filigrastim) product), Sandoz filed an opposition to Amgen's emergency motion for injunction pending en banc consideration and review. The opposition can be found here: Sandoz opposition 08-31-2015 — 17703935 v1. Sandoz argues that Amgen's emergency motion should be denied since […]
back to top